TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02439385
Drug: Avastin/FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avastin: 5mg/kg iv on day1, every 14 days. Irinotecan: 180 mg /m2 iv on day1, every 14 days. Leucovorin: 200 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil bolus: 400 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil infusion: 1200 mg/m2 iv on day1,2 every 14 days.
Study: NCT01690949
Drug: PUR118
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled PUR118, BID
Study: NCT02201823
Drug: ABTL0812
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABTL0812. Five cohorts and one extension phase.
Study: NCT03749642
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two capsules, three times a day, for 8 weeks.
Study: NCT00005860
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00923091
Drug: Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo
Normalized name: amlodipine / hydrochlorothiazide / olmesartan medoxomil Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
Study: NCT02140320
Drug: RV1729 single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of single dose
Study: NCT02140320
Drug: RV1729 matching placebo single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of single dose
Study: NCT02140320
Drug: RV1729 matching placebo 14 day repeat dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of repeat doses
Study: NCT02140320
Drug: RV1729 matching placebo 28 day repeat dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of repeat doses
Study: NCT00644319
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01670500
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered with doxorubicin intravenously every 2 or 3 weeks for 4 doses
Study: NCT01670500
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered with Cyclophosphamide intravenously every 2 or 3 weeks for 4 doses
Study: NCT00491530
Drug: ABT-335
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral coadministration of ABT-335 (135 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
Study: NCT00491530
Drug: rosuvastatin calcium
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral coadministration of rosuvastatin calcium (20 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
Study: NCT00491530
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral coadministration of simvastatin (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
Study: NCT03598777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The reconstituted solution will be injected intramuscularly across pelvic floor muscles.
Study: NCT01703312
Drug: QGE031
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug administered by subcutaneous injection
Study: NCT01703312
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug administered by subcutaneous injection
Study: NCT00649961
Drug: Melatonin injection
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single intravenous infusion of melatonin will be given to each infant over 6 hours so that successive groups will receive increasing doses until the correct dose for age is found.~Based on the pharmacokinetics and clearance of melatonin in adults an approximate dose has been calculated. The starting dose of melatonin will be 0.1 microgram/kg/hr to be given over 6 hours intravenously. The range of expected dose is 0.1-0.5 microgram/kg/hr.
Study: NCT02519231
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 440mg 1x pid
Study: NCT02519231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet 440mg 1x pid
Study: NCT01859351
Drug: WX-037
Normalized name: WX-554
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01859351
Drug: WX-554
Normalized name: WX-554
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03740217
Drug: GKT137831
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral bioavailable small molecule that selectively inhibit NOX1 and NOX4
Study: NCT03667131
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 5 mg tablet, every 12 hrs for 90 days.
Study: NCT01421368
Drug: Oral contraceptive: LNG 150 mcg and EE 30 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each pill contains LNG 150 mcg (the active levorotatory enantiomer of norgestrel) and EE 30 mcg. Each pack contains 21 active pills and 7 placebo pills
Study: NCT00315601
Drug: Telithromycin
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800 mg once a day for 5 days
Study: NCT00315601
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg on day 1, and then 250 mg once-daily on days 2 through 5
Study: NCT00315601
Drug: Telithromycin
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telithromycin 800 mg once a day
Study: NCT02862912
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups
Study: NCT00035815
Drug: Insulin like growth factor, type 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg per kg body weight given subcutaneously twice daily
Study: NCT00035815
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo represented the inert suspension vehicle for the IGF-1. It was given as equal volume as the active drug based upon body weight, subcutaneously twice daily.
Study: NCT03166800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This arm of the intervention the study subject will be administered placebo capsules to orally take every morning for 12 weeks.
Study: NCT03401606
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: remifentanil, 0.25 ng/mL, given intravenous, infusion, until surgery finished
Study: NCT00621023
Drug: Decitabine, Arsenic Trioxide and Ascorbic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive decitabine 20 mg/m2 IV over one hour for days1-5 of each cycle, and arsenic trioxide 0.25 mg/kg IV for days 1-5 of cycle 1 followed by 0.25 mg/kg twice weekly (Mon-Thursday or Tues-Fri) for all remaining cycles. Patients will have transfusion and supportive care therapy administered per the treating physician's discretion. Patients with a response after 4 cycles of therapy may choose to continue on two more cycles of decitabine with arsenic and ascorbic acid given only during the first week of those two additional cycles.
Study: NCT00749099
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 capsules of a placebo drug (Phase I) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each).
Study: NCT02513940
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days
Study: NCT02513940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo transdermal gel and placebo (lactose) capsules
Study: NCT01855230
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo b.i.d. for 14 days
Study: NCT03321617
Drug: Pomaglumetad methionil
Approvals — FDA: no, EMA: no, PMDA: no
Description: metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist
Study: NCT01794897
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.
Study: NCT00465140
Drug: creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04277702
Drug: Standard anti-platelet treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antithrombotic treatment for patients undergoing endovascular procedures
Study: NCT00936897
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 150mg PO QM (tablet)
Study: NCT03899870
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered neoadjuvant therapy. In the neoadjuvant therapy, we used 45 Gy in 25 fractions with concurrent 5-fluorouracil \[5-FU\] and patients were operated 8 to 10 weeks after neoadjuvant therapy. In some cases, especially the elderly patients with multiple co-morbidities, we used short-course pelvic radiation therapy which included 25 Gy in 5 fractions over 1 week.
Study: NCT04482673
Drug: Daily placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily
Study: NCT04482673
Drug: Bolus placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus placebo daily for 3 days
Study: NCT03090672
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline IV delivery
Study: NCT01133119
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will have femoral sheaths removed under general anesthetic but without subcutaneous infiltration of bupivacaine.
Study: NCT01804205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h
Study: NCT02260011
Drug: Atrovent® CFC inhalation aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04265534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo
Study: NCT03899870
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered adjuvant therapy. In most of the cases, FOLFOX (leucovorin, 5-FU, oxaliplatin) regimen was used and for elderly patients who could not tolerated this regimen, we used oral capecitabine.
Study: NCT01615445
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo daily for 4 weeks, followed by no medication for two weeks and then resveratrol 1 000 mg(500 mg twice) daily for 1 week, then by tolerance and safety 2 000 mg (1 000 mg twice) daily for three weeks.
Study: NCT02006030
Drug: Transarterial chemoembolization
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04173533
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral azacitidine (CC-486) matched placebo tablet
Study: NCT04382794
Drug: Retrospective case-control analysis
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Evaluation of clinical, laboratory and instrumental parameters of diabetic patients during hospitalization for COVID-19. The data will be extracted anonymously from the computerized medical records commonly used in clinical practice by the centers involved in the study
Study: NCT02908438
Drug: Gonadotrophin releasing hormone agonist(GnRHa)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.
Study: NCT04538014
Drug: [11C]-Lu AF88434
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[11C\]-Lu AF88434, and a radioactive dose not exceeding 400 MBq at each PET examination, intravenous bolus injection
Study: NCT02984501
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The induction phase of the treatment plan is designed to administer gemcitabine 1000 mg/mq and oxaliplatin 100 mg/mq every 14 days for four doses. Chemotherapy concurrent to conformal radiation therapy is gemcitabine at the dose of 600 mg/mq weekly.
Study: NCT01466114
Drug: estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules of 2 mg (total of 8 mg) PO QD
Study: NCT04252417
Drug: MD1003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose administration of MD1003 at Day 1
Study: NCT00000249
Drug: 20% N2O
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% inhaled N2O
Study: NCT00000249
Drug: 30% N2O
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% inhaled N2O
Study: NCT03900676
Drug: VB-1953 - 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Gel
Study: NCT01380093
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose, 2 x microcrystalline cellulose (weighed to equal weights of average tablet/capsule of active comparator) mixed with 150 ml artificially sweetened, non-carbonated beverage
Study: NCT00765115
Drug: LY450139
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00765115
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01822860
Drug: Chlorthalidone 12.5 mg
Normalized name: chlorthalidone 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01822860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03952650
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen likewise is not a part of the investigational product/regimen, but will be provided to participants in the chloroquine arm (Arm 4) if required to mitigate typical symptoms of malaria infection such as headache, myalgia, fever and chills.
Study: NCT01573468
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally once on Day 1 of each cycle
Study: NCT01573468
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1750 mg/m2/day orally twice daily (in 2 equally divided doses) on Days 1-14 of each cycle
Study: NCT03063255
Drug: Neuromuscular block
Normalized name: Neuromuscular blocking agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects allocated to the neuromuscular block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to PACU or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.
Study: NCT02296346
Drug: SoluMedrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of drug subcutaneously, once a month.
Study: NCT01722331
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to tildrakizumab PFS
Study: NCT01853449
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01853449
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline
Study: NCT01686711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01357239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02330029
Drug: Ledebouriella Root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledebouriella Root (\~10g)
Study: NCT02330029
Drug: Fingered citron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingered citron (\~10g)
Study: NCT02330029
Drug: Tuckahoe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuckahoe (15g)
Study: NCT02330029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is blindly given to patients.
Study: NCT03556761
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, PO, daily
Study: NCT00325572
Drug: oral zinc and vitamin C supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each child will be provided separate suspensions containing zinc and vitamin C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
Study: NCT00955240
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03894540
Drug: IPN60090
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules given daily
Study: NCT03876041
Drug: solumedrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous solution for injection
Study: NCT01054729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match sofosbuvir administered orally once daily
Study: NCT01154166
Drug: ReQuip PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: If subjects are still eligible at the end of the placebo run-in period they will be randomized (1:1) to receive once daily doses of ropinirole PR or identical appearing placebo tablets. Dosing will start at 2 mg ropinirole PR, or placebo equivalent. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control. All subjects must be titrated to a minimum dose of 6 mg/day.
Study: NCT01154166
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04603924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
Study: NCT01850381
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Placebo: Administer 6.4 mL Bacteriostatic saline by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
Study: NCT01479049
Drug: HP (High potassium) group
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hearts are arrested with cold blood cardioplegia with high potassium concentration (K+, 20mmol/L)during cardiac operation.
Study: NCT02441803
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 50 mg/kg by vein on Days +3 and +4.
Study: NCT03065530
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Normal saline control group receive NS after delivery. Drug: butorphanol tartrate PCA: butorphanol tartrate after cesarean section.
Study: NCT00950027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oropharyngeal decontamination every 4 hours
Study: NCT02873221
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment for a migraine as prescribed by the physician as standard of care in clinical practice.
Study: NCT01325493
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline given 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
Study: NCT01745055
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: individual dose of methotrexate (stably dosed)
Study: NCT01351519
Drug: Aminolevulinic Acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminolevulinic Acid will be administered as a single oral dose of 20mg/kg given in 50ml of water three hours before surgery.
Study: NCT02143271
Drug: KHK7580
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT00142103
Drug: CPG10101
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPG10101 subcutaneous, 0.20mg/kg, weekly, 12wks
Study: NCT00142103
Drug: CPG10101
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks
Study: NCT00142103
Drug: CPG10101
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
Study: NCT02203019
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl will be administered for analgesia in mechanically ventilated patients with sepsis. The use of Fentanyl is not an intervention of interest.
Study: NCT00006168
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04579393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets to match fostamatinib 100 mg and 150 mg will be provided.
Study: NCT00539721
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolapitant placebo (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
Study: NCT04146532
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 500mg placebo capsule.
Study: NCT00163137
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/day
Study: NCT00772967
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen tablets 500 mg twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Twice daily on Day 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.